Clearside Biomedical Submits New Drug Application for XIPERE for the Treatment of Macular Edema Associated with Uveitis
pharmaceutical investing Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update
pharmaceutical investing Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA
pharmaceutical investing Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
CHARBONE annonce la nomination de Patrick Cuddihy au poste de Vice-president principal - Affaires strategiques
